Table 2.
Focus group participants characteristics (N=28)
| Characteristic | N | % |
|---|---|---|
| Race | ||
| Black | 13 | 46 |
| White | 15 | 54 |
| Medication | ||
| Anastrozole | 24 | 86 |
| Exemestane | 3 | 11 |
| Letrozole | 1 | 4 |
| Stage | ||
| 0 | 4 | 14 |
| I | 12 | 43 |
| II | 9 | 32 |
| III | 3 | 11 |
| Number of months on AET (mean) | 10.1 | |
Focus group participants characteristics (N=28)
| Characteristic | N | % |
|---|---|---|
| Race | ||
| Black | 13 | 46 |
| White | 15 | 54 |
| Medication | ||
| Anastrozole | 24 | 86 |
| Exemestane | 3 | 11 |
| Letrozole | 1 | 4 |
| Stage | ||
| 0 | 4 | 14 |
| I | 12 | 43 |
| II | 9 | 32 |
| III | 3 | 11 |
| Number of months on AET (mean) | 10.1 | |